Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. | Read by QxMD (original) (raw)

Benjamin Terrier, Zahir Amoura, Philippe Ravaud, Eric Hachulla, Romain Jouenne, Bernard Combe, Christine Bonnet, Patrice Cacoub, Alain Cantagrel, Michel de Bandt, Olivier Fain, Bruno Fautrel, Philippe Gaudin, Bertrand Godeau, Jean-Robert Harlé, Arnaud Hot, Jean-Emmanuel Kahn, Olivier Lambotte, Claire Larroche, Jean Léone, Olivier Meyer, Béatrice Pallot-Prades, Edouard Pertuiset, Pierre Quartier, Thierry Schaerverbeke, Jean Sibilia, Alexandre Somogyi, Martin Soubrier, Eric Vignon, Brigitte Bader-Meunier, Xavier Mariette, Jacques-Eric Gottenberg

OBJECTIVE: A number of open-label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off-trial patients with SLE seen in regular clinical practice.

METHODS: We analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX.

RESULTS: One hundred thirty-six patients received treatment for SLE. The mean +/- SD score on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was 11.3 +/- 8.9 at baseline. Severe infections were noted in 12 patients (9%), corresponding to a rate of 6.6/100 patient-years. Most severe infections occurred within the first 3 months after the last RTX infusion. Five patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). Overall response was observed in 80 of 113 patients (71%) by the SELENA-SLEDAI assessment. Efficacy did not differ significantly between patients receiving RTX monotherapy and those receiving concomitant immunosuppressive agents (who had higher baseline disease activity). Articular, cutaneous, renal, and hematologic improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Among responders, 41% experienced a relapse of disease, with a response in 91% after retreatment with RTX.

CONCLUSION: Data from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE. The contrasting results with those from recent RCTs leave open the question of the therapeutic use of RTX in SLE. Additional controlled studies with new designs are needed to define the place of RTX in the therapeutic arsenal for SLE.